Proteomics identification of PGAM1 as a potential therapeutic target for urothelial bladder cancer

Peng, Xingchen; Gong, Fengming; Chen, Yunfeng; Meng, Qingcai; Cheng, Ke; Tang, Jie; Ge, Jun; Chen, N.; Zeng, Huawei; Liu, J.Y.

doi:10.1016/j.jprot.2015.11.027

Cited by 48 publications

(48 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Foregoing investigations have revealed PGAM1 overexpression in several cancers such as clear cell renal carcinoma (CCRC), glioma, oral squamous cell carcinoma (OSCC), breast cancer, human nonsmall lung cancer, pancreatic ductal adenocarcinoma, prostate cancer, colorectal cancer, hepatocellular carcinoma, and urothelial bladder cancer ( Table and Figure ).…”

Section: Overexpression Of Pgam1 In Various Cancersmentioning

confidence: 99%

“…27 Thus, PGAM1 has potential ability to derive the metastasis in a metabolic independent way. 31 breast cancer, 32 human nonsmall lung cancer, 33 pancreatic ductal adenocarcinoma, 34 prostate cancer, 35 colorectal cancer, 36 hepatocellular carcinoma, 14 and urothelial bladder cancer 37 ( Table 2 and Figure 3). In the hypoxia tumor microenvironment, cancer cells are oxygen independent for energy production.…”

Section: Nonmetabolic Functions Of Pgam1mentioning

confidence: 99%

See 1 more Smart Citation

Phosphoglycerate mutase 1 in cancer: A promising target for diagnosis and therapy

et al. 2019

View full text Add to dashboard Cite

Altered enzymatic machineries are a substantial biochemical characteristic of tumor cell metabolism that switch metabolic profile from oxidative phosphorylation to amplified glycolysis as well as increased lactate production under hypoxia conditions. Reprogrammed metabolic profile is an emerging hallmark of cancer. Overexpression of several glycolytic enzymes and glucose transporters has been reported in 24 different types of cancers that represent approximately 70% of all the cancer cases around the globe. Thus, targeting glycolytic enzymes could serve as tempting avenue for drug design against cancer. Phosphoglycerate mutase 1 (PGAM1) is an important glycolytic enzyme that catalyzes the conversion of 3‐phosphoglycerate to 2‐phosphoglycerate. Recent investigations have revealed the overexpression of PGAM1 in several human cancers that is linked with tumor growth, survival, and invasion. The aim of this review is to update scientific research network with cancer‐specific role of PGAM1 to elucidate its capability as bonafide therapeutic target for cancer therapy. Moreover, we have also summarized the reported genetic and pharmacological inhibitors of PGAM1. This study suggests that further investigations on PGAM1 should focus on the exploration of molecular mechanisms of PGAM1 overexpression in development of cancer, assessment of biosafety profiles of known inhibitors of PGAM1, and utilization of PGAM1 inhibitors in combinatorial therapies. These future studies will surely support the unbiased strategies for the development of novel PGAM1 inhibitors for cancer therapies.

show abstract

Section: Overexpression Of Pgam1 In Various Cancersmentioning

confidence: 99%

Section: Nonmetabolic Functions Of Pgam1mentioning

confidence: 99%

Phosphoglycerate mutase 1 in cancer: A promising target for diagnosis and therapy

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Initially, no clear indication for potential drug targets was reported. This concept, however, was recently addressed in a study by Peng et al where phosphoglycerate mutase 1 (PGAM1) was initially identified as significantly up‐regulated in BC compared to adjacent normal tissue by 2DE . Moreover, the protein level of PGAM1 has been found to be significantly correlated with the disease grade using IHC on a total of 90 tissue samples (i.e.…”

Section: Personalized Medicine In Bladder Cancermentioning

confidence: 99%

“…60 BC tissue and 30 adjacent normal tissue samples). The functional relevance and anti‐tumor potential upon inhibition was further investigated . Silencing of PGAM1 using shRNA decreased tumor growth and cell proliferation and increased apoptosis in vivo.…”

Section: Personalized Medicine In Bladder Cancermentioning

confidence: 99%

Clinical Proteomics for Precision Medicine: The Bladder Cancer Case

Latosinska

Frantzi

Vlahou

et al. 2017

Proteomics Clinical Apps

View full text Add to dashboard Cite

Precision medicine can improve patient management by guiding therapeutic decision based on molecular characteristics. The concept has been extensively addressed through the application of -omics-based approaches. Proteomics attract high interest, as proteins reflect a "real-time" dynamic molecular phenotype. Focusing on proteomics applications for personalized medicine, a literature search was conducted to cover: a) disease prevention, b) monitoring/ prediction of treatment response, c) stratification to guide intervention, and d) identification of drug targets. The review indicates the potential of proteomics for personalized medicine by also highlighting multiple challenges to be addressed prior to actual implementation. In oncology, particularly bladder cancer, application of precision medicine appears especially promising. The high heterogeneity and recurrence rates together with the limited treatment options, suggest that earlier and more efficient intervention, continuous monitoring, and the development of alternative therapies could be accomplished by applying proteomics-guided personalized approaches. This notion is backed by studies presenting biomarkers that are of value in patient stratification and prognosis, and by recent studies demonstrating the identification of promising therapeutic targets. Herein, we aim to present an approach whereby combining the knowledge on biomarkers and therapeutic targets in bladder cancer could serve as basis towards proteomics-guided personalized patient management.

show abstract

“…PGAM1 was significantly up-regulated in urothelial bladder cancer. Further analysis found that increased PGAM1 expression was correlated with severity of histological grade [72]. Using iTRAQ labelling coupled to LC-MS/MS, Chen et al identified 7 proteins with elevated expression in primary bladder cancer compared to adjacent non-tumorous tissue.…”

Section: Clinical Application In Cancermentioning

confidence: 99%

Proteomics and peptidomics: moving toward precision medicine in urological malignancies

2016

View full text Add to dashboard Cite

Urological malignancies are a major cause of morbidity and mortality worldwide. Advances in early detection, diagnosis, prognosis and prediction of treatment response can significantly improve patient care. Proteomic and peptidomic profiling studies are at the centre of kidney, prostate and bladder cancer biomarker discovery and have shown great promise for improved clinical assessment. Mass spectrometry (MS) is the most widely employed method for proteomic and peptidomic analyses. A number of MS platforms have been developed to facilitate accurate identification of clinically relevant markers in various complex biological samples including tissue, urine and blood. Furthermore, protein profiling studies have been instrumental in the successful introduction of several diagnostic multimarker tests into the clinic. In this review, we will provide a brief overview of high-throughput technologies for protein and peptide based biomarker discovery. We will also examine the current state of kidney, prostate and bladder cancer biomarker research as well as review the journey toward successful clinical implementation.

show abstract

Proteomics identification of PGAM1 as a potential therapeutic target for urothelial bladder cancer

Cited by 48 publications

References 17 publications

Phosphoglycerate mutase 1 in cancer: A promising target for diagnosis and therapy

Phosphoglycerate mutase 1 in cancer: A promising target for diagnosis and therapy

Clinical Proteomics for Precision Medicine: The Bladder Cancer Case

Proteomics and peptidomics: moving toward precision medicine in urological malignancies

Contact Info

Product

Resources

About